Cargando…

Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats

PURPOSE: To examine the effect of 3% diquafosol ophthalmic solution (DQS) on ocular surface disorders in diabetic model rats maintained in a continuous airflow condition. METHODS: Goto–Kakizaki (GK) rats, a spontaneous model of type 2 diabetes, were exposed to constant airflow for 8 weeks. After the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dota, Atsuyoshi, Sakamoto, Asuka, Nagano, Takashi, Murakami, Tadahiro, Matsugi, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132003/ https://www.ncbi.nlm.nih.gov/pubmed/32280196 http://dx.doi.org/10.2147/OPTH.S242764

Ejemplares similares

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh, Shizuka
Publicado: (2015)

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses
por: Nagahara, Yukiko, et al.
Publicado: (2015)

Short-term application of diquafosol ophthalmic solution benefits children with dry eye wearing orthokeratology lens
por: Yang, Yuanfang, et al.
Publicado: (2023)

Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
por: Ishikawa, Sho, et al.
Publicado: (2023)

A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients
por: Takamura, Etsuko, et al.
Publicado: (2012)

Diquafosol ophthalmic solution enhances mucin expression via ERK activation in human conjunctival epithelial cells with hyperosmotic stress
por: Lee, Hyun Jung, et al.
Publicado: (2022)

A randomised, prospective study of the effects of 3% diquafosol on ocular surface following cataract surgery
por: Kim, Sangyoon, et al.
Publicado: (2021)

Effects of 3% diquafosol sodium ophthalmic solution on higher-order aberrations in patients diagnosed with dry eye after cataract surgery
por: Inoue, Yasushi, et al.
Publicado: (2016)

Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
por: Mun, Yongseok, et al.
Publicado: (2018)

The Combined Impact of Intense Pulsed Light Combined and 3% Diquafosol Ophthalmic Solution on Evaporative Dry Eye: A Randomized Control Study
por: Chen, Jiayan, et al.
Publicado: (2023)

The effect of 3% diquafosol on the improvement of ocular surface post cataract surgery: A meta-analysis for time of intervention
por: Zhang, Yuhang, et al.
Publicado: (2022)

Correction: The Combined Impact of Intense Pulsed Light Combined and 3% Diquafosol Ophthalmic Solution on Evaporative Dry Eye: A Randomized Control Study
por: Chen, Jiayan, et al.
Publicado: (2023)

Sleep position and the ocular surface in a high airflow environment
por: Gauba, Vinod, et al.
Publicado: (2014)

The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)–knockout mice
por: Kojima, Takashi, et al.
Publicado: (2014)

Combination therapy with 3% diquafosol tetrasodium ophthalmic solution and sodium hyaluronate: an effective therapy for patients with dry eye after femtosecond laser-assisted in situ keratomileusis
por: Wang, Tianjiao, et al.
Publicado: (2023)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

Diquafosol tetrasodium elicits total cholesterol release from rabbit meibomian gland cells via P2Y(2) purinergic receptor signalling
por: Endo, Ken-ichi, et al.
Publicado: (2021)

Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study
por: Miyake, Kensaku, et al.
Publicado: (2017)

Ocular Surface Changes Associated with Ophthalmic Surgery
por: Mikalauskiene, Lina, et al.
Publicado: (2021)

Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study
por: Hori, Yuichi, et al.
Publicado: (2022)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Ocular surface microbiota: Ophthalmic infectious disease and probiotics
por: Chiang, Ming-Cheng, et al.
Publicado: (2022)

Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models
por: Dota, Atsuyoshi, et al.
Publicado: (2013)

Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients
por: Miyake, Hideki, et al.
Publicado: (2016)

Protocol for a parallel assignment prospective, randomised, comparative trial to evaluate the safety and efficacy of intense pulsed light (IPL) combined with 3% diquafosol (DQS) ophthalmic solution in dry eye syndrome
por: Chen, Jiayan, et al.
Publicado: (2023)

The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 (Sod1) Knockout Mice Treated with Antiglaucoma Eye Medications
por: Yagi-Yaguchi, Yukari, et al.
Publicado: (2020)

Topical diquafosol for patients with obstructive meibomian gland dysfunction
por: Arita, Reiko, et al.
Publicado: (2013)

Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
por: Schechter, Barry, et al.
Publicado: (2022)

Protecting the Ocular Surface in Cataract Surgery: The Efficacy of the Perioperative Use of a Hydroxypropyl Guar and Hyaluronic Acid Ophthalmic Solution
por: Favuzza, Eleonora, et al.
Publicado: (2020)

Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections
por: Opitz, Dominick L., et al.
Publicado: (2012)

Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation
por: Le Merdy, Maxime, et al.
Publicado: (2022)

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution
por: Cho, Hyung, et al.
Publicado: (2009)

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections
por: Kanda, Yoshiko, et al.
Publicado: (2012)

Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
por: Park, Chang Hyun, et al.
Publicado: (2019)

Allergy to ophthalmic solutions
por: Lapeere, Hilde, et al.
Publicado: (2014)

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence
por: Rajpal, Rajesh K, et al.
Publicado: (2014)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Ophthalmic Solutions with a Broad Antiviral Action: Evaluation of Their Potential against Ocular Herpetic Infections
por: Zannella, Carla, et al.
Publicado: (2022)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Long-term Rebamipide and Diquafosol in Two Cases of Immune-Mediated Dry Eye
por: Yamane, Mio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1hjjivie2i9muqsmljfb0f9tlo